The Experts below are selected from a list of 222 Experts worldwide ranked by ideXlab platform
Paola Bagnoli - One of the best experts on this subject based on the ideXlab platform.
-
infantile hemangiomas retinopathy of prematurity and cancer a common pathogenetic role of the β Adrenergic System
Medicinal Research Reviews, 2015Co-Authors: Luca Filippi, Giovanni Casini, Marta Daniotti, Federica Sereni, Massimo Dal Monte, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β‐Adrenergic System
Medicinal research reviews, 2014Co-Authors: Luca Filippi, Massimo Dal Monte, Giovanni Casini, Marta Daniotti, Federica Sereni, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
the β Adrenergic System as a possible new target for pharmacologic treatment of neovascular retinal diseases
Progress in Retinal and Eye Research, 2014Co-Authors: Giovanni Casini, Luca Filippi, Massimo Dal Monte, Irene Fornaciari, Paola BagnoliAbstract:Retinal neovascular pathologies, such as diabetic retinopathy, retinopathy of prematurity (ROP) and age-related macular degeneration, may be treated with intravitreal injections of drugs targeting vascular endothelial growth factor (VEGF), the main inducer of neoangiogenesis; however further improvements and alternative strategies are needed. In the last few years, an intense research activity has focused on the β-Adrenergic System. The results indicate that, in different experimental models, a decrease of the β-Adrenergic function may result either in reduction or in exacerbation of the vascular changes, thus suggesting possible dual effects of β-adrenoreceptor (β-AR) modulation depending on the experimental setting. In in vivo models of proliferative retinopathies, most of the data point to a strong inhibitory role against vascular changes exerted by the blockade of specific β-ARs. In particular, the β2-AR seems to be the mostly involved in these responses, and the β1-/β2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response. These observations have prompted clinical trials in preterm infants with ROP, where oral administrations of propranolol produced positive results in terms of efficacy, although safety problems were also reported. In addition, the possibility of using topical propranolol administrations in the form of eye drops opens new potential routes of drug administration in humans. A further point that should be considered is that there are data demonstrating significant antiapoptotic effects exerted by β-ARs, therefore if β-AR blockers were used to inhibit aberrant neovascularization, there may be a burden to pay in terms of impaired neuronal viability.
Silvia Moretti - One of the best experts on this subject based on the ideXlab platform.
-
The role of stress and beta-Adrenergic System in melanoma: current knowledge and possible therapeutic options
Journal of Cancer Research and Clinical Oncology, 2016Co-Authors: Roberta Colucci, Silvia MorettiAbstract:Purpose The aim of the present review was to discuss recent findings on the role of beta-Adrenergic System in melanoma, in order to provide information on the biological responses elicited by its activation and its potential application for melanoma treatment. Methods A literature search was performed, and evidences regarding the involvement of stress and beta-Adrenergic System in cancer and melanoma were found and discussed. Results Our search pointed out that beta-Adrenergic System is a key regulator of important biological processes involved in the onset and progression of some solid tumors. In the last decade, functional beta-adrenoceptors have been also identified on melanoma cells, as well as on their microenvironment cells. Similarly to other common cancers too, the activation of such adrenoceptors by catecholamines, usually released under stress conditions, has been found to trigger pro-tumorigenic pathways contributing to cell proliferation and motility, immune System regulation, apoptosis, epithelial–mesenchymal transition, invasion and neoangiogenesis. Conclusions The biological evidences we found clarify and sustain the clinical evidences reporting the involvement of chronic stress in melanoma onset and progression. In such scenario, it is conceivable that a therapeutic approach targeting beta-Adrenergic System could constitute a novel and promising strategy for melanoma treatment.
-
The role of stress and beta-Adrenergic System in melanoma: current knowledge and possible therapeutic options.
Journal of cancer research and clinical oncology, 2015Co-Authors: Roberta Colucci, Silvia MorettiAbstract:Purpose The aim of the present review was to discuss recent findings on the role of beta-Adrenergic System in melanoma, in order to provide information on the biological responses elicited by its activation and its potential application for melanoma treatment.
Luca Filippi - One of the best experts on this subject based on the ideXlab platform.
-
infantile hemangiomas retinopathy of prematurity and cancer a common pathogenetic role of the β Adrenergic System
Medicinal Research Reviews, 2015Co-Authors: Luca Filippi, Giovanni Casini, Marta Daniotti, Federica Sereni, Massimo Dal Monte, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β‐Adrenergic System
Medicinal research reviews, 2014Co-Authors: Luca Filippi, Massimo Dal Monte, Giovanni Casini, Marta Daniotti, Federica Sereni, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
the β Adrenergic System as a possible new target for pharmacologic treatment of neovascular retinal diseases
Progress in Retinal and Eye Research, 2014Co-Authors: Giovanni Casini, Luca Filippi, Massimo Dal Monte, Irene Fornaciari, Paola BagnoliAbstract:Retinal neovascular pathologies, such as diabetic retinopathy, retinopathy of prematurity (ROP) and age-related macular degeneration, may be treated with intravitreal injections of drugs targeting vascular endothelial growth factor (VEGF), the main inducer of neoangiogenesis; however further improvements and alternative strategies are needed. In the last few years, an intense research activity has focused on the β-Adrenergic System. The results indicate that, in different experimental models, a decrease of the β-Adrenergic function may result either in reduction or in exacerbation of the vascular changes, thus suggesting possible dual effects of β-adrenoreceptor (β-AR) modulation depending on the experimental setting. In in vivo models of proliferative retinopathies, most of the data point to a strong inhibitory role against vascular changes exerted by the blockade of specific β-ARs. In particular, the β2-AR seems to be the mostly involved in these responses, and the β1-/β2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response. These observations have prompted clinical trials in preterm infants with ROP, where oral administrations of propranolol produced positive results in terms of efficacy, although safety problems were also reported. In addition, the possibility of using topical propranolol administrations in the form of eye drops opens new potential routes of drug administration in humans. A further point that should be considered is that there are data demonstrating significant antiapoptotic effects exerted by β-ARs, therefore if β-AR blockers were used to inhibit aberrant neovascularization, there may be a burden to pay in terms of impaired neuronal viability.
Giovanni Casini - One of the best experts on this subject based on the ideXlab platform.
-
infantile hemangiomas retinopathy of prematurity and cancer a common pathogenetic role of the β Adrenergic System
Medicinal Research Reviews, 2015Co-Authors: Luca Filippi, Giovanni Casini, Marta Daniotti, Federica Sereni, Massimo Dal Monte, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β‐Adrenergic System
Medicinal research reviews, 2014Co-Authors: Luca Filippi, Massimo Dal Monte, Giovanni Casini, Marta Daniotti, Federica Sereni, Paola BagnoliAbstract:The serendipitous demonstration that the nonselective β-Adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-Adrenergic System in angiogenic processes. The efficacy of propranolol was related to the β2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Consequent to the encouraging animal studies, a pilot clinical trial showed that oral propranolol protects newborns from ROP progression, even though this treatment is not sufficiently safe. Further, animal studies clarified the role of β3-ARs in the development of ROP and, together with several preclinical studies demonstrating the key role of the β-Adrenergic System in tumor progression, vascularization, and metastasis, prompted us to also investigate the participation of β3-ARs in tumor growth. The aim of this review is to gather the recent findings on the role of the β-Adrenergic System in IHs, ROP, and cancer, highlighting the fact that these different pathologies, triggered by different pathogenic noxae, share common pathogenic mechanisms characterized by the presence of hypoxia-induced angiogenesis, which may be contrasted by targeting the β-Adrenergic System. The mechanisms characterizing the pathogenesis of IHs, ROP, and cancer may also be active during the fetal-neonatal development, and a great contribution to the knowledge on the role of β-ARs in diseases characterized by chronic hypoxia may come from research focusing on the fetal and neonatal period.
-
the β Adrenergic System as a possible new target for pharmacologic treatment of neovascular retinal diseases
Progress in Retinal and Eye Research, 2014Co-Authors: Giovanni Casini, Luca Filippi, Massimo Dal Monte, Irene Fornaciari, Paola BagnoliAbstract:Retinal neovascular pathologies, such as diabetic retinopathy, retinopathy of prematurity (ROP) and age-related macular degeneration, may be treated with intravitreal injections of drugs targeting vascular endothelial growth factor (VEGF), the main inducer of neoangiogenesis; however further improvements and alternative strategies are needed. In the last few years, an intense research activity has focused on the β-Adrenergic System. The results indicate that, in different experimental models, a decrease of the β-Adrenergic function may result either in reduction or in exacerbation of the vascular changes, thus suggesting possible dual effects of β-adrenoreceptor (β-AR) modulation depending on the experimental setting. In in vivo models of proliferative retinopathies, most of the data point to a strong inhibitory role against vascular changes exerted by the blockade of specific β-ARs. In particular, the β2-AR seems to be the mostly involved in these responses, and the β1-/β2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response. These observations have prompted clinical trials in preterm infants with ROP, where oral administrations of propranolol produced positive results in terms of efficacy, although safety problems were also reported. In addition, the possibility of using topical propranolol administrations in the form of eye drops opens new potential routes of drug administration in humans. A further point that should be considered is that there are data demonstrating significant antiapoptotic effects exerted by β-ARs, therefore if β-AR blockers were used to inhibit aberrant neovascularization, there may be a burden to pay in terms of impaired neuronal viability.
Richard G. Vernon - One of the best experts on this subject based on the ideXlab platform.
-
Chronic control of the β- and α2-Adrenergic Systems of sheep adipose tissue by growth hormone and insulin
Biochemical Journal, 1991Co-Authors: P W Watt, E Finley, S Cork, R A Clegg, Richard G. VernonAbstract:1. Sheep adipose tissue retained responsiveness to catecholamines when maintained in tissue culture for 48 h; both the rate of basal lipolysis and sensitivity to beta-agonists were increased after tissue culture. 2. Tissue culture in the presence of growth hormone resulted in an increased maximum response and sensitivity to the beta-agonist isoprenaline, but had no effect on basal lipolysis. 3. Tissue culture in the presence of insulin increased the basal rate of lipolysis and increased the ratio of the rate of noradrenaline-stimulated/isoprenaline-stimulated lipolysis, indicating a decrease in the 2-Adrenergic effect of noradrenaline. 4. Tissue culture in the presence of growth hormone increased ligand binding to beta-Adrenergic receptors. 5. Tissue culture in the absence of exogenous hormones increased ligand binding to alpha 2-Adrenergic receptors; this was prevented by actinomycin D and partly prevented by insulin. 6. These studies show that both growth hormone and insulin chronically modulate the Adrenergic System of sheep adipose tissue; the effects of growth hormone are primarily on the beta-Adrenergic System, whereas insulin modulates the alpha 2-Adrenergic System.
-
Chronic control of the beta- and alpha 2-Adrenergic Systems of sheep adipose tissue by growth hormone and insulin.
The Biochemical journal, 1991Co-Authors: P W Watt, E Finley, S Cork, R A Clegg, Richard G. VernonAbstract:1. Sheep adipose tissue retained responsiveness to catecholamines when maintained in tissue culture for 48 h; both the rate of basal lipolysis and sensitivity to beta-agonists were increased after tissue culture. 2. Tissue culture in the presence of growth hormone resulted in an increased maximum response and sensitivity to the beta-agonist isoprenaline, but had no effect on basal lipolysis. 3. Tissue culture in the presence of insulin increased the basal rate of lipolysis and increased the ratio of the rate of noradrenaline-stimulated/isoprenaline-stimulated lipolysis, indicating a decrease in the 2-Adrenergic effect of noradrenaline. 4. Tissue culture in the presence of growth hormone increased ligand binding to beta-Adrenergic receptors. 5. Tissue culture in the absence of exogenous hormones increased ligand binding to alpha 2-Adrenergic receptors; this was prevented by actinomycin D and partly prevented by insulin. 6. These studies show that both growth hormone and insulin chronically modulate the Adrenergic System of sheep adipose tissue; the effects of growth hormone are primarily on the beta-Adrenergic System, whereas insulin modulates the alpha 2-Adrenergic System.
